Free Trial

eFFECTOR Therapeutics (EFTRW) Competitors

eFFECTOR Therapeutics logo

EFTRW vs. ATNFW, SXTPW, DRTSW, WENAW, APLMW, BCTXW, CDIOW, CTCXW, CELUW, and CEROW

Should you be buying eFFECTOR Therapeutics stock or one of its competitors? The main competitors of eFFECTOR Therapeutics include 180 Life Sciences (ATNFW), 60 Degrees Pharmaceuticals (SXTPW), Alpha Tau Medical (DRTSW), Anew Medical (WENAW), Apollomics (APLMW), BriaCell Therapeutics (BCTXW), Cardio Diagnostics (CDIOW), Carmell (CTCXW), Celularity (CELUW), and CERo Therapeutics (CEROW). These companies are all part of the "biotechnology" industry.

eFFECTOR Therapeutics vs.

180 Life Sciences (NASDAQ:ATNFW) and eFFECTOR Therapeutics (NASDAQ:EFTRW) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, community ranking, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

In the previous week, 180 Life Sciences had 1 more articles in the media than eFFECTOR Therapeutics. MarketBeat recorded 1 mentions for 180 Life Sciences and 0 mentions for eFFECTOR Therapeutics. 180 Life Sciences' average media sentiment score of 1.87 beat eFFECTOR Therapeutics' score of 0.00 indicating that 180 Life Sciences is being referred to more favorably in the media.

Company Overall Sentiment
180 Life Sciences Very Positive
eFFECTOR Therapeutics Neutral

180 Life Sciences and eFFECTOR Therapeutics both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
180 Life SciencesN/AN/A
eFFECTOR TherapeuticsN/AN/A

Company Net Margins Return on Equity Return on Assets
180 Life SciencesN/A N/A N/A
eFFECTOR Therapeutics N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
180 Life SciencesN/AN/AN/AN/AN/A
eFFECTOR TherapeuticsN/AN/AN/AN/AN/A

Summary

180 Life Sciences beats eFFECTOR Therapeutics on 2 of the 2 factors compared between the two stocks.

Get eFFECTOR Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for EFTRW and its competitors with MarketBeat's FREE daily newsletter.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EFTRW vs. The Competition

MetriceFFECTOR TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$150.91M$5.15B$8.74B
Dividend YieldN/A3.64%5.18%4.08%
P/E RatioN/A187.6762.6013.00
Price / SalesN/A16,673.191,277.9088.72
Price / CashN/A12.4639.7935.27
Price / BookN/A7.886.455.92
Net IncomeN/A-$20.05M$119.73M$225.73M

eFFECTOR Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EFTRW
eFFECTOR Therapeutics
N/AN/AN/AN/A$0.00N/A0.0014
ATNFW
180 Life Sciences
N/A$0.01
flat
N/A-32.5%$0.00N/A0.007Gap Up
High Trading Volume
SXTPW
60 Degrees Pharmaceuticals
N/A$0.01
flat
N/A-26.0%$0.00$418,304.000.002Positive News
DRTSW
Alpha Tau Medical
N/A$0.20
flat
N/A-37.3%$0.00N/A0.0080News Coverage
WENAW
Anew Medical
N/A$0.04
-0.3%
N/AN/A$0.00N/A0.00N/AGap Down
APLMW
Apollomics
N/A$0.01
-63.3%
N/A-81.2%$0.00N/A0.0059Short Interest ↓
Positive News
Gap Up
High Trading Volume
BCTXW
BriaCell Therapeutics
N/A$0.27
flat
N/A-81.4%$0.00N/A0.008Short Interest ↓
Gap Down
CDIOW
Cardio Diagnostics
N/A$0.04
flat
N/A-63.6%$0.00$39,138.000.007Positive News
Gap Down
CTCXW
Carmell
N/A$0.11
flat
N/AN/A$0.00$12,320.000.009Positive News
CELUW
Celularity
N/A$0.02
-15.5%
N/A+64.5%$0.00$42.69M0.00220Positive News
Gap Up
CEROW
CERo Therapeutics
N/A$0.01
flat
N/AN/A$0.00N/A0.008Short Interest ↓
Positive News
Gap Up
High Trading Volume

Related Companies and Tools


This page (NASDAQ:EFTRW) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners